Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 64 Neoplasms 8 Sarcoma 6 Ovarian Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Glioma 4 Carcinoma, Non-Small-Cell Lung 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Prostatic Neoplasms 3 Osteosarcoma 3 Neuroblastoma 3 Melanoma 3 Medulloblastoma 3 Lymphoma 3 Liposarcoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Wilms Tumor 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lung Neoplasms 2 Kidney Neoplasms 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × palbociclib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡